Multiple myeloma (MM), a blood cancer of plasma cells with an incidence of over 30,000 cases and 12,000 deaths per year [1], has been treated with targeted immunotherapies to CS1 [2], BCMA [3], and CD38 antigens [4], but each has met with eventual recurrence. Here, SLAMF7 is linked to Miyoshi myopathy.